The association between TP53 rs1625895 polymorphism and the risk of sarcopenic obesity in Iranian older adults: a case-control study.
Body mass index
Obesity
Polymorphism
Sarcopenia
p53
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
13 May 2021
13 May 2021
Historique:
received:
22
12
2020
accepted:
30
04
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Aging and obesity are the two major global health concerns. Sarcopenia, an age-linked disease, wherein a progressive loss of muscle volume, muscle strength, and physical activity occurs. In this study we evaluated the association of TP53 rs1625895 polymorphism with the susceptibility to sarcopenic obesity in Iranian old-age subjects. Total of 176 old individuals (45 sarcopenic and 131 healthy) were recruited in this research and genotyped by PCR-RFLP. BMI, Skeletal Muscle Mass Index, body composition, Handgrip Strength, Gait Speed (GS), and biochemical parameters were measured. Chi-square test was done for genotypes and alleles frequency. Linear regression was applied to find the correlation between TP53 rs1625895 polymorphism, and biochemical and anthropometric parameters. The correlation between TP53 rs1625895 and the risk of sarcopenia and sarcopenic obesity was investigated by logistic regression. G allele was significantly higher in sarcopenic obesity group [P = 0.037, OR (CI 95%) = 1.9 (1.03-3.5)] compared to A allele. BMI (P = 0.049) and LDL (P = 0.04) were significantly differed between genotypes when GG was compared to AA/AG genotype. The results revealed when GG genotype compared to AA/AG genotype in adjusted model for age, the risk of sarcopenic obesity [P value = 0.011, OR (CI 95%); 2.72 (1.25-5.91)] increased. Similarly, GG/AG genotype increased the risk of sarcopenic obesity [P value = 0.028, OR (CI 95%); 2.43 (1.10-5.36)] in adjusted model for age compared to AA genotype. We suggested that TP53 rs1625895 polymorphism may increase the risk of sarcopenic obesity in Iranian population.
Sections du résumé
BACKGROUND
BACKGROUND
Aging and obesity are the two major global health concerns. Sarcopenia, an age-linked disease, wherein a progressive loss of muscle volume, muscle strength, and physical activity occurs. In this study we evaluated the association of TP53 rs1625895 polymorphism with the susceptibility to sarcopenic obesity in Iranian old-age subjects.
METHODS
METHODS
Total of 176 old individuals (45 sarcopenic and 131 healthy) were recruited in this research and genotyped by PCR-RFLP. BMI, Skeletal Muscle Mass Index, body composition, Handgrip Strength, Gait Speed (GS), and biochemical parameters were measured. Chi-square test was done for genotypes and alleles frequency. Linear regression was applied to find the correlation between TP53 rs1625895 polymorphism, and biochemical and anthropometric parameters. The correlation between TP53 rs1625895 and the risk of sarcopenia and sarcopenic obesity was investigated by logistic regression.
RESULTS
RESULTS
G allele was significantly higher in sarcopenic obesity group [P = 0.037, OR (CI 95%) = 1.9 (1.03-3.5)] compared to A allele. BMI (P = 0.049) and LDL (P = 0.04) were significantly differed between genotypes when GG was compared to AA/AG genotype. The results revealed when GG genotype compared to AA/AG genotype in adjusted model for age, the risk of sarcopenic obesity [P value = 0.011, OR (CI 95%); 2.72 (1.25-5.91)] increased. Similarly, GG/AG genotype increased the risk of sarcopenic obesity [P value = 0.028, OR (CI 95%); 2.43 (1.10-5.36)] in adjusted model for age compared to AA genotype.
CONCLUSIONS
CONCLUSIONS
We suggested that TP53 rs1625895 polymorphism may increase the risk of sarcopenic obesity in Iranian population.
Identifiants
pubmed: 33985476
doi: 10.1186/s12891-021-04314-5
pii: 10.1186/s12891-021-04314-5
pmc: PMC8120782
doi:
Substances chimiques
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
438Commentaires et corrections
Type : ErratumIn
Références
Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Sarcopenia: an overview. Aging Clin Exp Res. 2017;29(1):11–7. https://doi.org/10.1007/s40520-016-0704-5 .
doi: 10.1007/s40520-016-0704-5
pubmed: 28155183
Pratt J, Boreham C, Ennis S, Ryan AW, De Vito G. Genetic Associations with Aging Muscle: A Systematic Review. Cells. 2019;9:1.
doi: 10.3390/cells9010012
Urano T, Shiraki M, Sasaki N, Ouchi Y, Inoue S. Large-scale analysis reveals a functional single-nucleotide polymorphism in the 5′-flanking region of PRDM16 gene associated with lean body mass. Aging Cell. 2014;13(4):739–43. https://doi.org/10.1111/acel.12228 .
doi: 10.1111/acel.12228
pubmed: 24863034
pmcid: 4326941
Garatachea N, Fiuza-Luces C, Torres-Luque G, Yvert T, Santiago C, Gomez-Gallego F, et al. Single and combined influence of ACE and ACTN3 genotypes on muscle phenotypes in octogenarians. Eur J Appl Physiol. 2012;112(7):2409–20. https://doi.org/10.1007/s00421-011-2217-4 .
doi: 10.1007/s00421-011-2217-4
pubmed: 22045415
Liao ZY, Chen JL, Xiao MH, Sun Y, Zhao YX, Pu D, et al. The effect of exercise, resveratrol or their combination on sarcopenia in aged rats via regulation of AMPK/Sirt1 pathway. Exp Gerontol. 2017;98:177–83. https://doi.org/10.1016/j.exger.2017.08.032 .
doi: 10.1016/j.exger.2017.08.032
pubmed: 28847722
Nasimi N, Dabbaghmanesh MH, Sohrabi Z. Nutritional status and body fat mass: determinants of sarcopenia in community-dwelling older adults. Exp Gerontol. 2019;122:67–73. https://doi.org/10.1016/j.exger.2019.04.009 .
doi: 10.1016/j.exger.2019.04.009
pubmed: 31022445
S-h H, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci. 2020;21(2):494.
doi: 10.3390/ijms21020494
Xie W-q, G-l X, Y-b F, He M, Lv S, Li Y-S. Sarcopenic obesity: research advances in pathogenesis and diagnostic criteria. Aging Clin Exp Res. 2019:1–6.
Kemp GJ, Birrell F, Clegg PD, Cuthbertson DJ, De Vito G, van Dieen JH, et al. Developing a toolkit for the assessment and monitoring of musculoskeletal ageing. Age Ageing. 2018;47(suppl_4):iv1–iv19.
doi: 10.1093/ageing/afy143
Zempo H, Miyamoto-Mikami E, Kikuchi N, Fuku N, Miyachi M, Murakami H. Heritability estimates of muscle strength-related phenotypes: a systematic review and meta-analysis. Scand J Med Sci Sports. 2017;27(12):1537–46. https://doi.org/10.1111/sms.12804 .
doi: 10.1111/sms.12804
pubmed: 27882617
Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol. 2010;28(14):2467–74. https://doi.org/10.1200/JCO.2009.26.6213 .
doi: 10.1200/JCO.2009.26.6213
pubmed: 20368557
pmcid: 2881725
Reiling E, Lyssenko V, Boer JM, Imholz S, Verschuren WM, Isomaa B, et al. Codon 72 polymorphism (rs1042522) of TP53 is associated with changes in diastolic blood pressure over time. Eur J Med Genet. 2012;20(6):696–700. https://doi.org/10.1038/ejhg.2011.240 .
doi: 10.1038/ejhg.2011.240
Leu JI, Murphy ME, George DL. The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver. J Liver. 2013;2(1).
Schwarzkopf M, Coletti D, Marazzi G, Sassoon D. p53 activity induces muscle atrophy and stem cell perturbation. Basic Applied Myology. 2008;18(5):131–8.
Shafiee G, Asgari Y, Soltani A, Larijani B, Heshmat R. Identification of candidate genes and proteins in aging skeletal muscle (sarcopenia) using gene expression and structural analysis. PeerJ. 2018;6:e5239. https://doi.org/10.7717/peerj.5239 .
doi: 10.7717/peerj.5239
pubmed: 30202641
pmcid: 6129146
Di Renzo L, Gratteri S, Sarlo F, Cabibbo A, Colica C, De Lorenzo A. Individually tailored screening of susceptibility to sarcopenia using p53 codon 72 polymorphism, phenotypes, and conventional risk factors. Dis Markers. 2014;2014:743634.
doi: 10.1155/2014/743634
Assad Samani L, Javadirad S-M, Parsafar S, Tabatabaeian H, Ghaedi K, Azadeh M. TP53 rs1625895 is related to breast Cancer incidence and early death in Iranian population. Indian J Clin Biochem. 2019;34(4):485–9. https://doi.org/10.1007/s12291-018-0774-6 .
doi: 10.1007/s12291-018-0774-6
pubmed: 31686737
Malmer BS, Feychting M, Lonn S, Lindstrom S, Gronberg H, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neuro Oncol. 2007;82(3):229–37. https://doi.org/10.1007/s11060-006-9275-1 .
doi: 10.1007/s11060-006-9275-1
Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomark Prev. 2007;16(2):214–22. https://doi.org/10.1158/1055-9965.EPI-06-0790 .
doi: 10.1158/1055-9965.EPI-06-0790
Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, et al. Genetic variation in TP53 and risk of breast cancer in a population-based case–control study. Carcinogenesis. 2007;28(8):1680–6. https://doi.org/10.1093/carcin/bgm097 .
doi: 10.1093/carcin/bgm097
pubmed: 17449902
Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis. 2013;4(2):e492. https://doi.org/10.1038/cddis.2013.24 .
doi: 10.1038/cddis.2013.24
pubmed: 23412385
pmcid: 3734845
Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101. https://doi.org/10.1016/j.jamda.2013.11.025 .
doi: 10.1016/j.jamda.2013.11.025
pubmed: 24461239
Low S, Goh KS, Ng TP, Ang SF, Moh A, Wang J, et al. The prevalence of sarcopenic obesity and its association with cognitive performance in type 2 diabetes in Singapore. Clin Nutr. 2019.
https://www.ncbi.nlm.nih.gov/ .
Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, et al. p53 genotypes and haplotypes associated with lung Cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94(9):681–90. https://doi.org/10.1093/jnci/94.9.681 .
doi: 10.1093/jnci/94.9.681
pubmed: 11983757
Montazeri-Nafafabady N, Dabbaghmanesh MH, Mohamadian Amiri R, Bakhshayeshkaram M, Ranjbar OG. Influence of LRP5 (rs556442) polymorphism on insulin resistance in healthy Iranian children and adolescents. Turk J Med Sci. 2019;49(2):490–6. https://doi.org/10.3906/sag-1809-107 .
doi: 10.3906/sag-1809-107
pubmed: 30866603
Dolgin E. The most popular genes in the human genome. Nature. 2017;551(7681):427–31. https://doi.org/10.1038/d41586-017-07291-9 .
doi: 10.1038/d41586-017-07291-9
pubmed: 29168817
Mello SS, Attardi LD. Deciphering p53 signaling in tumor suppression. Curr Opin Cell Biol. 2018;51:65–72. https://doi.org/10.1016/j.ceb.2017.11.005 .
doi: 10.1016/j.ceb.2017.11.005
pubmed: 29195118
Mazzaro G, Bossi G, Coen S, Sacchi A, Soddu S. The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells. Oncogene. 1999;18(42):5831–5. https://doi.org/10.1038/sj.onc.1202962 .
doi: 10.1038/sj.onc.1202962
pubmed: 10523864
Voropaeva EN, Voevoda MI, Pospelova TI, Maksimov VN. Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients. Br J Haematol. 2015;169(1):32–5. https://doi.org/10.1111/bjh.13237 .
doi: 10.1111/bjh.13237
pubmed: 25430047
Mukhammadiyeva GF, Karimov DO, Bakirov AB, Karimova LK. TP53 gene polymorphisms and occupational skin Cancer risks for workers of glass Fiber manufacture. Iran J Public Health. 2017;46(11):1495–501.
pubmed: 29167767
pmcid: 5696688
Ortega FJ, Moreno-Navarrete JM, Mayas D, Serino M, Rodriguez-Hermosa JI, Ricart W, et al. Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression. Int J Obes (2005). 2014;38(5):737–45.
doi: 10.1038/ijo.2013.163
Krstic J, Reinisch I, Schupp M, Schulz TJ, Prokesch A. p53 functions in adipose tissue metabolism and homeostasis. Int J Mol Sci. 2018;19(9):2622. https://doi.org/10.3390/ijms19092622 .
doi: 10.3390/ijms19092622
pmcid: 6165290
Yahagi N, Shimano H, Matsuzaka T, Najima Y, Sekiya M, Nakagawa Y, et al. p53 activation in adipocytes of obese mice. J Biol Chem. 2003;278(28):25395–400. https://doi.org/10.1074/jbc.M302364200 .
doi: 10.1074/jbc.M302364200
pubmed: 12734185
Sabir JSM, El Omri A, Shaik NA, Banaganapalli B, Hajrah NH, Zrelli H, et al. The genetic association study of TP53 polymorphisms in Saudi obese patients. Saudi J Biol Sci. 2019;26(7):1338–43. https://doi.org/10.1016/j.sjbs.2019.04.006 .
doi: 10.1016/j.sjbs.2019.04.006
pubmed: 31762593
pmcid: 6864141
Kung CP, Basu S, Murphy ME. A link between TP53 polymorphisms and metabolism. Mol Cell Oncol. 2016;3(4):e1173769. https://doi.org/10.1080/23723556.2016.1173769 .
doi: 10.1080/23723556.2016.1173769
pubmed: 27652322
pmcid: 4972101
Wang X, Huang G, Mei S, Qian J, Ji J, Zhang J. Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma. Biochem Biophys Res Commun Title. 2009;380(2):286–91. https://doi.org/10.1016/j.bbrc.2009.01.060 .
doi: 10.1016/j.bbrc.2009.01.060
Jeng C, Zhao L-J, Wu K, Zhou Y, Chen T, Deng H-W. Race and socioeconomic effect on sarcopenia and sarcopenic obesity in the Louisiana osteoporosis study (LOS). JCSM Clin Rep. 2018;3(2):e00027.
pubmed: 31463425
pmcid: 6712972
Kung CP, Leu JI, Basu S, Khaku S, Anokye-Danso F, Liu Q, et al. The P72R polymorphism of p53 predisposes to obesity and metabolic dysfunction. Cell Rep. 2016;14(10):2413–25. https://doi.org/10.1016/j.celrep.2016.02.037 .
doi: 10.1016/j.celrep.2016.02.037
pubmed: 26947067
pmcid: 4926645
Gloria-Bottini F, Banci M, Saccucci P, Magrini A, Bottini E. Is there a role of p53 codon 72 polymorphism in the susceptibility to type 2 diabetes in overweight subjects? A study in patients with cardiovascular diseases. Diabetes Res Clin Pract. 2011;91(3):e64–7. https://doi.org/10.1016/j.diabres.2010.11.031 .
doi: 10.1016/j.diabres.2010.11.031
pubmed: 21146884
Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol. 2011;13(3):310–6. https://doi.org/10.1038/ncb2172 .
doi: 10.1038/ncb2172
pubmed: 21336310
pmcid: 3110666
Maddocks OD, Vousden KH. Metabolic regulation by p53. J Mol Med. 2011;89(3):237–45. https://doi.org/10.1007/s00109-011-0735-5 .
doi: 10.1007/s00109-011-0735-5
pubmed: 21340684